Prostate cancer. Incidence, management and outcomes

Drugs and Aging

Volumn 13, Issue 1, 1998, Pages 71-81

  Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; CORTICOSTEROID; DOXORUBICIN; ESTRAMUSTINE; HYDROCORTISONE; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; SURAMIN;

ANEMIA; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SENSITIVITY; FATIGUE; HOT FLUSH; HUMAN; IMPOTENCE; LIFE EXPECTANCY; MALE; OBESITY; OSTEOPOROSIS; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REFERENCE VALUE; RISK ASSESSMENT;

ADULT; AGED; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; UNITED STATES;

EID: 0031857509     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199813010-00007     Document Type: Article

References (66)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. CA Cancer J Clin 1996; 65: 5-27
2. Mettlin C, Murphy GP, Ho R, et al. The National Cancer Database report on longitudinal observations on prostate cancer. Cancer 1996; 77: 2162-6
3. Stephenson R, Smart CR, Mineau GP, et al. The fall in incidence of prostate carcinoma: on the down side of a prostate specific antigen induced peak in incidence - data from the Utah Cancer Registry. Cancer 1996; 77: 1342-8
4. Haas GP, Sakr WA. Epidemiology of prostate cancer. CA Cancer J Clin 1997; 47: 273-88
5. Giovannuci E, Aschero A, Rimm EB, et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995; 87: 1767-76
6. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome I suggested by a genomewide search. Science 1996; 274: 1371-4
7. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20
8. Kadmon D, Williams RH, Pavlik VN, et al. Pitfalls in interpreting prostate specific antigen velocity. J Urol 1996; 155: 1655-7
9. Morgan TO, Jacobsen SJ, McCarthy WF, et al. Age-specific reference ranges for prostate-specific antigen in black men [comments]. N Engl J Med 1996; 335: 304-10
10. Partin AW, Criley SR, Subong EN, et al. Standard versus age-specific antigen reference ranges among men with clinically localized prostate cancer: a pathological analysis. J Urol 1996; 155: 1336-9
11. Adolfsson J, Carstensen J, Lowhagen T. Deferred treatment in clinically localized prostatic carcinoma. Br J Urol 1992; 69: 183-7
12. Aus G, Hugosson J, Norlen L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995; 154: 460-5
13. Catalona W, Smith D, Wolfert R, et al. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20
14. Demura TS, Tanaka M, Enami N, et al. The proportion of free to total prostate specific antigen induced peak in incidence-data from the Utah Cancer Registry. Utah Cancer Registry 1996; 77: 1342-8
15. Filella XA, Molina R, Gimenez N, et al. Clinical usefulness of free PSA fraction as an indicator of prostate cancer. Int J Cancer 1995; 63: 780-4
16. Oesterling JE, Jacobsen SJ, Klee GG, et al. Free, complexed, and total serum prostate specific antigen: the establishment of appropriate reference ranges for the concentrations and ratios. J Urol 1995; 154: 1594-8
17. Lerner SJ, Lilja H, Bergstralh EJ, et al. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology 1996; 48: 240-8
18. Schwartz KL, Severson RK, Gurney JG, et al. Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994. Cancer 1996; 78: 1260-6
19. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason Score to predict pathological state of localized prostate cancer: a multi-institutional update. JAMA 1997; 277: 1445-51
20. Olsson CA, de Vries GM, Raffo AJ, et al. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol 1996; 155: 1661-2
21. Seiden MV, Kantoff PW, Krithivas K, et al. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 1994; 12: 2634-9
22. Robinson JW, Dufour MS, Fung TS. Erectile functioning of men treated for prostate cancer. Cancer 1997; 79: 5338-44
23. Eastham JA, Kattan MW, Rogers E, et al. Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996; 156: 1707-13
24. Soloway M, Sharifi R, Wajsman Z, et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 1995; 154: 424-8
25. Labrie F, Cusan L, Gomez JL, et al. Neoadjuvant hormonal therapy: the Canadian experience. Urology 1997; 49: 56-64
26. Abbas F, Scardino PT. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol Clin North Am 1996; 23: 587-604
27. Witjes WP, Schulman CC, Debruyne FM. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 1997; 49: 65-9
28. Bazinet M, Zheng W, Begin LR, et al. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology 1997; 49: 721-5
29. Pilepich M, Krall JM, Al-Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616-23
30. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300
31. Roach M III, Meehan S, Kroll S, et al. Radiotherapy for high grade clinically localized carcinoma of the prostate. J Urol 1996; 156: 1719-23
32. Dillioglugil O, Leibman BD, Kattan MW, et al. Comparative long-term outcomes after various management strategies for T1-2 prostate cancer: a hazard rate (HR) analysis [abstract]. Proc Am Urol Assn 1996; 155: 558
33. Chodak G, Thisted RA. Comparison of cancer specific survival (CSS) follow ing radical prostatectomy (RP) or watchful waiting (WW) based on two multi-institutional pooled analyses [abstract]. Proc Am Urol Assn 1996; 155: 559
34. Yao S, Lu-Yao G. Survival following curative or conservative management in patients diagnosed with clinically localized prostate cancer [abstract]. Proc Am Soc Clin Oncol 1996; 15: 253
35. Wilt TJ, Brawer MK. The prostate cancer intervention versus observation trial (PIVOT). Oncology 1997; 11: 1133-9
36. Petrovich Z, Lieskovsky G, Freeman J, et al. Surgery with adjuvant irradiation in patients with pathologic stage C adenocarcinoma of the prostate. Cancer 1996; 76: 1621-8
37. Syndikus I, Pickles T, Kostashuk E, et al. Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. J Urol 1996; 155: 1983-6
38. Fowler J, Pandey P, Seaver L, et al. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995; 154: 448-53
39. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-9
40. Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998; 51: 137-44
41. Higano CS, Ellis W, Russell K, et al. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996; 48: 800-4
42. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235-46
43. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome: experience in a large cohort of unselected advanced prostate cancer patients. Cancer 1995; 76: 1428-34
44. Kelly WK, Scher HI, Mazumdar M. Prostate specific antigen as a measure of disease outcome in metastatic hormone refractory prostate cancer. J Clin Oncol 1993; 11: 607-15
45. Figg WD, Sartor O, Cooper MR, et al. Prostate specific antigen decline following discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 1995; 98: 412-4
46. Taplin ME, Bubley GJ, Shuster TD, et al. Androgen receptor mutations in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332: 1393-8
47. Small EJ, Carroll PR. Prostate specific antigen decline after Casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43: 408-10
48. Dawson N, Small EJ, Winer EP. Megestrol acetate (MA) in men with hormone-refractory prostate cancer (HRPC): prostate specific antigen (PSA) response and antiandrogen withdrawal (AAWD) data: a Cancer and Leukemia Group B study. Proc Am Soc Clin Oncol 1996; 15: 241
49. Kelly W, Curley T, Leibertz C, et al. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995; 13: 2208-13
50. Small E, Baron A, Fippin L, et al. Ketoconazole retains activity in hormone refractory prostate cancer. J Urol 1997; 157: 1204-7
51. Eisenberger MA, Nelson WG. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! J Natl Cancer Inst 1996; 88: 779-81
52. Figg W, Ammerman K, Patronas N, et al. Lack of correlation between prostate specific antigen and the presence of measurable soft tissue metastases in hormone refractory prostate cancer. Cancer Invest 1996; 14: 513-7
53. Pienta KJ, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12: 2005-12
54. Petrylak DP, Shelton G, Judge T, et al. Phase I trial of estramustine + docetaxel androgen-insensitive prostate cancer [abstract]. Proc Am Soc Clin Oncol 1997; 16: 310
55. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone refractory prostate cancer. J Clin Oncol 1997; 15: 3156-63
56. Kobayashi K, Vokes E, Vogelzang NV. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 1995; 13: 2196-207
57. Reyno LE, Egorin MJ, Eisenberger MA, et al. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 1995; 13: 2187-95
58. Rosen P, Mendoza EF, Landaw EM, et al. Suramin in hormone refractory metastatic prostate cancer: a drug with limited efficacy. J Clin Oncol 1996; 14: 1626-36
59. Small EJ, Marshall ME, Reyno L, et al. Superiority of suramin + hydrocortisone over placebo + hydrocortisone: results of a multi-center double-blind phase III study in patients with hormone refractory prostate cancer [abstract]. Proc Am Soc Clin Oncol 1998; 17: 308a
60. Tannock I, Osoba D, Stocker MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64
61. Kantoff P, Conoway M, Winer E, et al. Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer: preliminary results from a prospective randomized Cancer and Leukemia Group B study [abstract]. Proc Am Soc Clin Oncol 1996; 15: 25
62. Small EJ, Srinivas S, Egan B, et al. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone resistant prostate cancer. J Clin Oncol 1996; 14: 1617-25
63. Kim SI, Chen DC, Muggia FM. A new look at radionuclides therapy in metastatic disease of bone (review and prospects). Anticancer Res 1988; 8 (4): 681-4
64. Robinson RG, Blake GM, Preston DF, et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographies 1989; 9 (2): 271-81
65. Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991; 64 (765): 816-22
66. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25 (5): 805-13